Premium
Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy
Author(s) -
Sait Sameer,
Zaghloul Nibal,
Patel Ashish,
Shah Tishi,
Iacobas Ionela,
Calderwood Stanley
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25189
Subject(s) - medicine , chelation therapy , adverse effect , tertiary care , serum ferritin , blood transfusion , pediatric oncology , ferritin , cancer , intensive care medicine , thalassemia
We conducted a retrospective chart review to determine prevalence of, risk factors for, and liver toxicity associated with Transfusion Related Iron Overload (TRIO) in pediatric cancer patients, and report our experience with Iron Chelation Therapy (ICT). Total number of transfusions was identified as the major risk factor, with a prevalence of 37% in patients receiving ≥10 transfusions. Four patients with TRIO and abnormal liver function tests (LFT) received ICT. Significant decrease in serum ferritin and improvement in LFT were observed, with no serious adverse effects from ICT noted. Guidelines for screening and treatment of TRIO in pediatric oncology are needed. Pediatr Blood Cancer 2014;61:2319–2320. © 2014 Wiley Periodicals, Inc.